STATIN-FIBRATE REPORT: Focus on Safety

VHA Pharmacy Benefits Management-Strategic Healthcare Group and The Medical Advisory Panel . Executive Summary: (Key Questions) Efficacy. Is there evidence to demonstrate an advantage with regard to reducing coronary health outcomes in patients receiving a combination of statins plus fibrates compared to statins alone (e.g. especially in patients with TG in the 300 range-metabolic syndrome) to ... ................
................